- Home
- NNVC
NNVC
NanoViricides Inc.
as 07-05-2024 1:36pm EST
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SHELTON |
| Market Cap: | 26.3M | IPO Year: | N/A |
| Target Price: | $6.50 | AVG Volume (30 days): | 443.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $3.59 | Next Earning Date: | 05-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NanoViricides Inc. News
NNVC Breaking Stock News: Dive into NNVC Ticker-Specific Updates for Smart Investing
ACCESSWIRE
11 days ago
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
ACCESSWIRE
15 days ago
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model
ACCESSWIRE
24 days ago
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
ACCESSWIRE
a month ago
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
ACCESSWIRE
a month ago
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
ACCESSWIRE
a month ago
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
ACCESSWIRE
2 months ago
Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure
Associated Press Finance
2 months ago
NanoViricides: Fiscal Q3 Earnings Snapshot
Share on Social Networks:
Disclaimer
The information presented on this page, "NNVC NanoViricides Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.